|
Market Cap | 211.72M | EPS (ttm) | - |
P/E | - | EPS this Y | 90.18% |
Forward P/E | - | EPS next Y | -15.16% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 46.38% | Inst Own | 13.43% |
Insider Trans | 9.70% | Inst Trans | - |
Short Float | 7.12% | Earnings | May 13/b |
Analyst Recom | 1.00 | Target Price | 23.00 |
Avg Volume | 220.54K | 52W Range | 8.53 - 15.24 |
|
|
|
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Apr 02 '24 | Buy | 16.00 | 312,500 | 5,000,000 | 1,884,787 | Apr 04 04:15 PM | ARCH Venture Fund IX, L.P. | 10% Owner | Apr 02 '24 | Buy | 16.00 | 200,000 | 3,200,000 | 1,181,766 | Apr 04 04:30 PM | CRANDELL KEITH | 10% Owner | Apr 02 '24 | Buy | 16.00 | 200,000 | 3,200,000 | 1,181,766 | Apr 04 04:30 PM | Burow Kristina | Director | Apr 02 '24 | Buy | 16.00 | 200,000 | 3,200,000 | 1,181,766 | Apr 04 04:30 PM |
|
|
|
|
Market Cap | 90.61M | EPS (ttm) | -1.92 |
P/E | - | EPS this Y | -14.22% |
Forward P/E | - | EPS next Y | -1.57% |
PEG | - | EPS past 5Y | - |
P/S | 111.87 | EPS next 5Y | - |
P/B | 0.49 | EPS Q/Q | 20.23% |
Dividend | - | Sales Q/Q | -100.00% |
Insider Own | 7.61% | Inst Own | 17.56% |
Insider Trans | 0.00% | Inst Trans | 53.96% |
Short Float | 0.05% | Earnings | May 13/b |
Analyst Recom | 1.50 | Target Price | 7.40 |
Avg Volume | 23.97K | 52W Range | 1.64 - 5.10 |
|
|
|
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Scheeren Joseph | Director | Jun 26 '23 | Buy | 2.44 | 10,000 | 24,400 | 23,000 | Jun 28 07:52 AM | Wright Robin | Director | May 25 '23 | Buy | 2.66 | 13,750 | 36,612 | 48,256 | Jun 01 04:33 PM |
|
|
|
|
Market Cap | 630.62M | EPS (ttm) | -1.24 |
P/E | - | EPS this Y | -14.09% |
Forward P/E | 14.86 | EPS next Y | 115.69% |
PEG | - | EPS past 5Y | - |
P/S | 1.90 | EPS next 5Y | - |
P/B | 1.90 | EPS Q/Q | 92.05% |
Dividend | - | Sales Q/Q | 14.98% |
Insider Own | 74.44% | Inst Own | 4.25% |
Insider Trans | 0.00% | Inst Trans | -0.08% |
Short Float | 5.87% | Earnings | May 13/b |
Analyst Recom | 1.00 | Target Price | 13.31 |
Avg Volume | 1.49M | 52W Range | 2.77 - 14.65 |
|
|
|
Blue Safari Group Acquisition Corp. is as a blank check company, which was created for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on February 23, 2021 and is headquartered in Hong Kong. |
|
| |
|
Market Cap | 3.17B | EPS (ttm) | - |
P/E | - | EPS this Y | -49.96% |
Forward P/E | 7.86 | EPS next Y | 34.61% |
PEG | - | EPS past 5Y | 12.69% |
P/S | - | EPS next 5Y | - |
P/B | 1.39 | EPS Q/Q | - |
Dividend | 0.88% | Sales Q/Q | - |
Insider Own | 14.20% | Inst Own | 48.54% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.78% | Earnings | May 13/b |
Analyst Recom | 1.00 | Target Price | 20.03 |
Avg Volume | 967.95K | 52W Range | 11.78 - 17.70 |
|
|
|
Burford Capital Ltd. engages in the provision of legal finance products and services comprising core legal finance and alternative strategies, and in the asset management business. It operates through following segments: Capital Provision, Asset Management and Other Services, and Other Corporate. The Capital Provision segment provides capital to the legal industry or in connection with legal matters, both directly and through investment in the Group's private funds. The Asset Management and Other Services segment offers services to the legal industry including litigation insurance. The Other Corporate segment includes certain operating and non-operating activities that are not used internally to measure and evaluate the performance of the reportable segments. The company was founded by Christopher P. Bogart, Elizabeth O'Connell, and Jonathan T. Molot on September 11, 2009 and is headquartered in St. Peter Port, Guernsey. |
|
|
|
Market Cap | 1.51B | EPS (ttm) | 2.31 |
P/E | 4.31 | EPS this Y | 350.00% |
Forward P/E | 8.67 | EPS next Y | 6.48% |
PEG | 0.15 | EPS past 5Y | -3.51% |
P/S | 1.76 | EPS next 5Y | 29.60% |
P/B | 1.45 | EPS Q/Q | 2026.99% |
Dividend | 1.60% | Sales Q/Q | 172.54% |
Insider Own | - | Inst Own | 3.87% |
Insider Trans | - | Inst Trans | - |
Short Float | 0.59% | Earnings | May 13/b |
Analyst Recom | 3.00 | Target Price | 30.15 |
Avg Volume | 367.61K | 52W Range | 4.74 - 11.60 |
|
|
|
Central Puerto SA engages in the generation and distribution of electricity. It operates through the following segments: Electric Power Generation from Conventional Sources; Electric Power Generation from Renewable Sources; Natural Gas Transport and Distribution; and Others. The Natural Gas Transport and Distribution segment provides natural gas distribution public sector service in the Cuyo and Centro regions of Argentina and it is also engaged in the natural gas transport sector service. The company was founded in 1989 and is headquartered in Buenos Aires, Argentina. |
|
| |
|
Market Cap | 192.09M | EPS (ttm) | -0.24 |
P/E | - | EPS this Y | 362.60% |
Forward P/E | 9.69 | EPS next Y | 30.62% |
PEG | - | EPS past 5Y | - |
P/S | 1.39 | EPS next 5Y | - |
P/B | 0.80 | EPS Q/Q | 72.94% |
Dividend | 5.59% | Sales Q/Q | 12.98% |
Insider Own | 37.04% | Inst Own | 28.00% |
Insider Trans | 0.00% | Inst Trans | -0.95% |
Short Float | 1.40% | Earnings | May 13/b |
Analyst Recom | 1.00 | Target Price | 13.75 |
Avg Volume | 40.71K | 52W Range | 8.91 - 14.34 |
|
|
|
Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, Jersey. |
|
|
|
Market Cap | 214.64M | EPS (ttm) | -0.35 |
P/E | - | EPS this Y | -26.84% |
Forward P/E | - | EPS next Y | -10.92% |
PEG | - | EPS past 5Y | 12.88% |
P/S | - | EPS next 5Y | - |
P/B | 1.37 | EPS Q/Q | -27.42% |
Dividend | - | Sales Q/Q | - |
Insider Own | 37.34% | Inst Own | 38.56% |
Insider Trans | 0.00% | Inst Trans | 2.93% |
Short Float | 1.91% | Earnings | May 13/b |
Analyst Recom | 1.43 | Target Price | 8.83 |
Avg Volume | 355.59K | 52W Range | 1.15 - 3.62 |
|
|
|
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA. |
|
| |
|
Market Cap | 17.59M | EPS (ttm) | -1.90 |
P/E | - | EPS this Y | -22.73% |
Forward P/E | - | EPS next Y | 14.81% |
PEG | - | EPS past 5Y | -1.25% |
P/S | - | EPS next 5Y | - |
P/B | 0.67 | EPS Q/Q | 20.61% |
Dividend | - | Sales Q/Q | - |
Insider Own | 30.03% | Inst Own | 6.87% |
Insider Trans | 0.00% | Inst Trans | -2.54% |
Short Float | 0.11% | Earnings | May 13/b |
Analyst Recom | 1.00 | Target Price | 8.00 |
Avg Volume | 16.05K | 52W Range | 1.33 - 3.29 |
|
|
|
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA. |
|
|
|
Market Cap | 22.84M | EPS (ttm) | 0.01 |
P/E | 146.91 | EPS this Y | 400.00% |
Forward P/E | 7.44 | EPS next Y | 220.00% |
PEG | - | EPS past 5Y | - |
P/S | 0.60 | EPS next 5Y | - |
P/B | 2.84 | EPS Q/Q | -103.09% |
Dividend | - | Sales Q/Q | -50.97% |
Insider Own | 91.92% | Inst Own | 0.04% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.41% | Earnings | May 13/b |
Analyst Recom | 1.00 | Target Price | 4.00 |
Avg Volume | 75.94K | 52W Range | 0.92 - 6.90 |
|
|
|
Cheetah Net Supply Chain Service, Inc. operates as a supply chain company. Its services include warehousing, logistics, international trading and supply chain finance. The company was founded by Huan Liu on August 9, 2016 and is headquartered in Charlotte, NC. |
|
|
|
Market Cap | 329.13M | EPS (ttm) | -0.02 |
P/E | - | EPS this Y | 210.34% |
Forward P/E | 12.92 | EPS next Y | 207.80% |
PEG | - | EPS past 5Y | 51.93% |
P/S | 0.12 | EPS next 5Y | 3.27% |
P/B | 6.10 | EPS Q/Q | 117.12% |
Dividend | - | Sales Q/Q | -4.31% |
Insider Own | 19.88% | Inst Own | 11.75% |
Insider Trans | 0.00% | Inst Trans | 3.66% |
Short Float | 1.42% | Earnings | May 13/b |
Analyst Recom | 2.38 | Target Price | 1.81 |
Avg Volume | 355.88K | 52W Range | 1.07 - 4.08 |
|
|
|
Dingdong (Cayman) Ltd. operates as an on-demand e-commerce company. The firm provides users with fresh produce, meat and seafood, and other daily necessities through a convenient and excellent shopping experience supported by an extensive self-operated frontline fulfillment grid. It also provides other daily necessities to grow into a one-stop online shopping destination in China for consumers to make purchases for their daily lives. The Company was founded by Liang Changlin in October 2018 and is headquartered in Shanghai, China. |
|
|